(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Reconnecting with an old friend is a story of distance, loss and rediscovery- Cognizant Couture d: A Survey of \Moral Decisions and Sharp Looks\ Maintainable Style
- Don't miss Jupiter shining close to the waning gibbous moon on Dec. 7
- 6 Exceptionally Appraised Summer Travel Objections
- 7 Espresso Machines for Home Baristas
- Israel says 40 Hezbollah members killed as forces advance in Lebanon
- CDC advisory panel delays vote on hepatitis B vaccines after unruly meeting
- The next frontier in space is closer than you think – welcome to the world of very low Earth orbit satellites
- The Significance of Health Projects in Senior Protection.
